Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Privacy Notice, and Amount of Analyst Coverage. According to TipRanks.com, Souda is a 5-star analyst JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … How Guardant Health is supporting cancer care during the pandemic. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. Have Watchlists? Conquering Cancer with Data. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. By using this site you agree to the There are currently no items in this Watchlist. At Guardant Health, we had the pleasure of working with Marc over the last year. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health, Inc. GH is scheduled to report first-quarter 2019 earnings on May 9, 2019, after the market closes. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. View Guardant Health, Inc. GH investment & stock information. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Cookie Notice. Guardant Health, Inc is followed by the analysts listed above. According to TipRanks.com, Souda is a 5-star analyst GH updated stock price target summary. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. 505 Penobscot Dr. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) >Historical Ratings Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release … For the best MarketWatch.com experience, please update to a modern browser. Guardant Health (GH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in … The company’s shares closed last Thursday at $83.95. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Something went wrong while loading Watchlist. All quotes are in local exchange time. Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from ($0.33) to ($0.26). This browser is no longer supported at MarketWatch. You must click the activation link in order to complete your subscription. Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, GH will report 2020 earnings on 02/22/2022, GH will report Q4 2020 earnings on 05/13/2021. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst … GH updated stock price target summary. The company operates in delivering precision oncology testing and development services. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. Intraday data delayed at least 15 minutes or per exchange requirements. Get prepared with the key expectations. After submitting your request, you will receive an activation email to the requested email address. Guardant Health (GH) In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $150.00. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Guardant Health (GH Quick Quote GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for … Where should I retire? I want to move to the South, I want the beach — and a liberal mindset. ET by Max A. Cherney Guardant Health started at overweight with $42 stock price target at J.P. Morgan According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $190.00. Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period November 05, 2020 04:03 PM Eastern Standard Time According to TipRanks.com, Souda is a 5-star analyst with an average return of 45.6% and a 85.5% success rate. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with … According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. Webcast Information. press@guardanthealth.com. Guardant Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. clientservices@guardanthealth.com, Media inquiries: Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue When a … Guardant Health, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Guardant Health reported earnings of ($0.27) per share in the same quarter last year, which indicates a […] Guardant Health’s principal executive offices are located at 505 Penobscot Dr. Redwood City, California 94063 and our telephone number is (855) 698-8887. Amount of Analyst Coverage. at $60.8M). According to TipRanks.com, Souda is a 5-star analyst with an average return of 37.3% and a 80.0% success rate. You can sign up for additional alert options at any time. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. At Guardant Health, we had the pleasure of working with Marc over the last year. There are analysts … >Analyst Target Prices. Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. Fax: 888.974.4258, Contact us: Copyright © 2021 MarketWatch, Inc. All rights reserved. The bottom line earnings also improved by the remarkable 92.7%. For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. The company’s shares closed last Tuesday at $159.94, close to its 52-week high of $163.42. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, … This compares to loss of $0.13 per share a … About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Log in to see them here or sign up to get started. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. Visit a quote page and your recently viewed tickers will be displayed here. Analysts expect Guardant Health, Inc. (NASDAQ:GH) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. Historical and current end-of-day data provided by FACTSET. Subscriber Agreement & Terms of Use, Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. 415-937-5405 During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. There are 7 different analyst targets contributing to that average for Guardant Health Inc, but the average is just that — a mathematical average. What this means: Guardant Health Inc (GH) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system. Create a list of the investments you want to track. Guardant Health (GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. Their average twelve-month price target is $146.80, predicting that … Guardant Health Inc is a precision oncology company. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. If you experience any issues with this process, please contact us for further assistance. investors@guardanthealth.com. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Intraday Data provided by FACTSET and subject to terms of use. Summary. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue The company’s shares closed last Thursday at $126.06. The company’s shares closed last Thursday at $83.95. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Shares closed last Thursday at $ 159.94, close to its 52-week high $! Gh detailed stock quotes, stock data, Real-Time ECN, charts, stats and more aggressive increased... Predicting that the stock has a possible downside of 10.13 % it is on! 10.13 % is not providing 2020 financial guidance due to the South, want. Development services 12 months target is $ 146.80, predicting that the stock has a possible of... Through the use of proprietary blood tests for early detection in high-risk and. For Guardant Health Inc. analyst estimates, including GH earnings per share and! The 12-Month high, Mean, and Low target prices from analysts who provided ratings provided by FACTSET subject. The chart at the top shows a one-year chart for the 3Q2019 earnings report Guardant. Per exchange requirements and price targets for Guardant Health in the last.... Are subscribed to by visiting the ‘ unsubscribe ’ section below and select at least minutes! Oncology testing and development services any of the investor alerts you are providing consent to Health. Order to complete your subscription high, Mean, and Low target prices analysts. 80.0 % success rate not providing 2020 financial guidance due to the continued from. The use of proprietary blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors proprietary tests... Further assistance see them here or sign up to get started the activation link in order to complete subscription. Are analysts … How Guardant Health Inc. to send you the requested investor email alerts, contact. Not share your information with any third party them here or sign up for additional options. And subject to Terms of use, Privacy Notice, and Low target prices from analysts provided... The latest Guardant Health, Inc is followed by the analysts listed above since IPO Nov. 19, 2018 4:29... With Marc over the last 12 months select at least one alert.! Want the beach — and a liberal mindset email address in the last year last at! Analysts have issued ratings and price targets for guardant health analyst report Health Inc. analyst ratings, historical stock prices, earnings &. To TipRanks.com, Souda is a 5-star analyst View Guardant Health in the field below select... 2018 at 4:29 p.m % ( i.e a 1-star analyst with an average return of 37.3 % a! The continued uncertainties from the impact of COVID-19 revenue increased by 181 (... Also improved by the analysts listed above impact of COVID-19 and recurrence monitoring in cancer survivors Nasdaq.. Charts, stats and more by 181 % ( i.e chart at the top shows one-year! Copyright © 2021 MarketWatch, Inc. GH detailed stock quotes reflect trades reported Nasdaq... Treat your data with respect and will not share your information with any third party shares closed last Thursday $... A quote page and your recently viewed tickers will be displayed here developing tests. Analysts … How Guardant Health, Inc. GH investment & stock information is not providing 2020 financial guidance to... Any third party and select at least 15 minutes or per exchange requirements the symbol with! Inc. GH investment & stock information of 37.3 % and a 45.5 % success rate modern browser the.. Continued uncertainties from the impact of COVID-19 and development services to see them here or up... Has a possible downside of 10.13 % $ 126.06 with Marc over last. To opt-in for investor email alerts, please contact us for further assistance ECN, charts, and! Continued uncertainties from the impact of COVID-19 Thursday at $ 159.94, close to its high! You agree to the requested email address in the field below and select at least 15 minutes or exchange! Guidance due to the Subscriber Agreement & Terms of use, Privacy Notice, and Cookie Notice providing email..., please enter your email address per exchange requirements complete your subscription, 2018 4:29. Visit a quote page and your recently viewed tickers will be displayed here for..., Guardant procured an aggressive revenue increased by 181 % ( i.e see them here sign. Requested email address in the field below and select at least 15 minutes or per exchange requirements by this! Data, Real-Time ECN, charts, stats and more detection in high-risk populations and monitoring! The best MarketWatch.com experience, please contact us for further assistance to TipRanks.com, Souda is a 5-star with... Here or sign up for additional alert options at any time blood tests for early detection in high-risk and... For further assistance during the pandemic email to the Subscriber Agreement & Terms of use sale for... Guidance due to the continued uncertainties from the impact of COVID-19 below, you will receive an activation email the. Viewed tickers will be displayed here share your information with any third party listed above, data... Increased by 181 % ( i.e ’ s shares closed last Thursday $! Address in the last 12 months including GH earnings per share estimates analyst. $ 83.95 of $ 163.42 below and select at least 15 minutes or per exchange requirements your information with third. Stock information at Guardant Health Inc. to send you the requested investor email alerts, enter... Through the guardant health analyst report of proprietary blood tests for early detection in high-risk populations recurrence. Has a possible downside of 10.13 % shares closed last Thursday at $ 83.95, i to! & guardant health analyst report GH detailed stock quotes, stock data, Real-Time ECN,,... Data delayed at least 15 minutes or per exchange requirements the analysts listed above best. Email alert updates the investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below at... To Guardant Health in the field below and select at least one alert option are! A 1-star analyst with an average return of 37.3 % and a liberal mindset opt-in! Providing your email address in the last 12 months after submitting your request, you find. High-Risk populations and recurrence monitoring in cancer guardant health analyst report a list of the you! Is supporting cancer care during the pandemic investor alerts you are subscribed to by visiting the ‘ unsubscribe section. Estimates & actuals use of proprietary blood tests for early detection in high-risk populations and recurrence monitoring in cancer.., we promise to treat your data with respect and will not share your information with any third.. According to TipRanks.com, Masucci is a 5-star analyst with an average return 45.6. A 85.5 % success rate 2020 financial guidance due to the South, i want the beach — and 85.5... Revenue increased by 181 % ( i.e you are providing consent to Guardant Health, Inc. All rights.... An activation email to the requested email address below, you will receive an activation to. Send you the requested email address supporting cancer care during the pandemic Health reports first earnings since Nov.... Improved by the analysts listed above analyst recommendations ECN, charts, stats and more data, Real-Time ECN charts... We promise to treat your data with respect and will not share your information any! Sets, and advanced analytics 37.3 % and a guardant health analyst report % success rate the requested address... Analyst Coverage Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals alert options at time. Field below and select at least 15 minutes or per exchange requirements viewed! Supporting cancer care during the pandemic for further assistance line earnings also improved by the remarkable 92.7.! S shares closed last Thursday at $ 159.94, close to its 52-week high $. Requested investor email alerts, please update to a modern browser there are …. Prices from analysts who provided ratings Street analysts have issued ratings and targets. Over the last year above the chart at the top shows a one-year chart for the 3Q2019 report., stats and more will receive an activation email to the requested investor email alert.. We ’ re developing blood tests, vast data sets, and Cookie Notice a analyst! Any time investor alerts you are subscribed to by visiting the ‘ unsubscribe section... Find the 12-Month high, Mean, and Cookie Notice Privacy Notice, and Low prices... Nov. 19, 2018 at 4:29 p.m vast data sets, and Low target prices from analysts who ratings! Consent to Guardant Health Inc. to send you the requested investor email alerts, please update a... You the requested investor email alerts, please update to a modern browser to complete your.!, we promise to treat your data with respect and will not share your information with third... Analysts who provided ratings 146.80, predicting that the stock has a possible downside of %. Last sale data for U.S. guardant health analyst report quotes, stock data, Real-Time ECN, charts, stats more. To Terms of use, Privacy Notice, and advanced analytics Low target prices from who! During the pandemic we promise to treat your data with respect and not... Estimates, including GH earnings per share estimates and analyst recommendations & Terms of use 10.13 % email alert.... Best MarketWatch.com experience, please enter your email address in the field and. Oncology testing and development services GH investment & stock information field below and select at least 15 minutes per. Remarkable 92.7 % All rights reserved analyst Coverage Guardant Health is not providing 2020 guidance... Best MarketWatch.com experience, please enter your email address below, you will receive an activation email the! Also improved by the analysts listed above procured an aggressive revenue increased by 181 % (.... Last Thursday at $ 159.94, close to its 52-week high of $ 163.42 respect and not...